GLP-1s vs Traditional Weight Loss Medications Older options like phentermine, orlistat, or naltrexone-bupropion typically produce 5-10% weight loss compared to 15-22% with GLP-1 medications
** Based on the treatment policy estimand: treatment effect regardless of if patients stayed on treatment or took other weight loss therapies
Lets break it down: Ozempic (semaglutide): Approved for type 2 diabetes
In practical terms: Men with mild low testosterone may see normalization Men with moderate deficiencies may see partial improvement Men with severe hypogonadism often still require TRT Results depend on treatment consistency, weight loss progress, sleep quality, stress levels, and underlying medical conditions
Novo Nordisk first synthesized semaglutide and brought it into clinical development, recognizing its potential as a longer-acting and more potent alternative to earlier GLP-1 analogs like liraglutide (Victoza)
While the implementation of subgroup analysis based on individual SLP-1 RAs appears to significantly enhance the clinical acceptability of these findings by differentiating the potential risk profiles of individual drugs, it seems to be involved in a significant enhancement of the clinical acceptability of these findings